Research Papers:

Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line

Zheng-Hai Tang _, Xiao-Ming Jiang, Xia Guo, Chi Man Vivienne Fong, Xiuping Chen and Jin-Jian Lu

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:81598-81610. https://doi.org/10.18632/oncotarget.13150

Metrics: PDF 4690 views  |   HTML 4673 views  |   ?  


Zheng-Hai Tang1,*, Xiao-Ming Jiang1,*, Xia Guo1, Chi Man Vivienne Fong1, Xiuping Chen1, Jin-Jian Lu1

1State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China

*These authors have contributed equally to this work

Correspondence to:

Jin-Jian Lu, email: [email protected]

Keywords: osimertinib, AZD9291, EGFR, navitoclax, NSCLC

Received: July 04, 2016    Accepted: October 17, 2016    Published: November 07, 2016


Osimertinib (OSI, also known as AZD9291) is the newest FDA-approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. However, resistance to OSI is likely to progress and the study of potential OSI-resistant mechanisms in advanced is necessary. Here, the OSI-resistant NCI-H1975/OSIR cells were established. After cells developed resistance to OSI, cell proliferation was decreased while cell migration and invasion were increased. The NCI-H1975/OSIR cells exhibited more resistance to gefitinib, erlotinib, afatinib, rociletinib, doxorubicin, and fluorouracil, meanwhile showing higher sensitivity to paclitaxel, when compared with NCI-H1975 cells. In addition, the NCI-H1975/OSIR cells did not display multidrug resistance phenotype. The activation and expression of EGFR were decreased after cells exhibited resistance. Compared with NCI-H1975 cells, the activation of ERK and AKT in NCI-H1975/OSIR cells could not be significantly inhibited by OSI treatment. Navitoclax (ABT-263)-induced cell viability inhibition and apoptosis were more significant in NCI-H1975/OSIR cells than that in NCI-H1975 cells. Moreover, these effects of navitoclax in NCI-H1975/OSIR cells could be reversed by pretreatment of Z-VAD-FMK. Collectively, loss of EGFR could pose as one of the OSI-resistant mechanisms and navitoclax might be the candidate drug for OSI-resistant NSCLC patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13150